Mechanistic Studies in Human Subcutaneous Adipose Tissue

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY

The investigator recently showed that the glycan-binding adipokine galectin-1 increased during overfeeding and that galectin-1 independently could predict type 2 diabetes. Further, the molecules that induce insulin release in the fasting state when blood glucose is normal remain elusive. It is possible that galectin-1 is involved in adaptive mechanisms in adipose tissue in obese subjects.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 70
Healthy Volunteers: t
View:

• Men and women of age: 40.0 - 70.0 years

• BMI: 18.0 - 25.0 kg/m2 (lean subjects) and BMI 30.0 - 38.0 kg/m2 (Ob-IS and Ob-IR)

• Fasting insulin \< 9.0 mU/l (lean and Ob-IS subjects) and fasting insulin \> 9.0 mU/l (Ob-IR)

• Fasting glucose \< 6.1 mmol/l

• Body temperature \< 37.5°C

• First-degree relative with known T2D in Ob-IR

• Weight stable ± 5 kg \< 3 months before screening

• Fluent in Swedish and can follow given instructions

• Consent given to participate

Locations
Other Locations
Sweden
Gothia Forum CTC
RECRUITING
Gothenburg
Contact Information
Primary
Per-Anders E Jansson, Prof
per-anders.jansson@wlab.gu.se
46 70 203 30 10
Backup
Vagner R Silva, PhD
vagner.silva@wlab.gu.se
46 76 849 77 03
Time Frame
Start Date: 2023-05-05
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 45
Treatments
Obese insulin-sensitive subjects (Ob-IS)
Obese Insulin Sensitive subjects (BMI \> 30 kg/m2, fasting insulin \< 9.0 mU/l and fasting plasma glucose \< 6.1 mmol/l) undergoing subcutaneous microdialysis, needle biopsy, glucose clamp and MRI.
Obese insulin-resistant subjects (Ob-IR)
Obese Insulin Resistant subjects (BMI \> 30 kg/m2, fasting insulin \> 9.0 mU/l and fasting plasma glucose \< 6.1 mmol/l) undergoing subcutaneous microdialysis, needle biopsy, glucose clamp and MRI.
Lean healthy controls (Lean)
Lean healthy controls (BMI \< 25 kg/m2, fasting insulin \< 9.0 mU/l and fasting plasma glucose \< 6.1 mmol/l) undergoing subcutaneous microdialysis, needle biopsy, glucose clamp and MRI.
Related Therapeutic Areas
Sponsors
Leads: Vastra Gotaland Region
Collaborators: Göteborg University

This content was sourced from clinicaltrials.gov